Clinical Trials Logo

Filter by:
NCT ID: NCT04388540 Completed - Iodine Deficiency Clinical Trials

Caribbean Island Urinary Iodine Survey 2018

CRUISE
Start date: January 1, 2018
Phase:
Study type: Observational

Many of the Caribbean island nations have no data on iodine status in their populations. Iodine deficiency in children can reduce IQ but can be easily corrected through a program of salt iodization. The study will be located at 11 islands of the Caribbean region. At each of the 11 study sites, we will measure the iodine status in school-age children by collecting morning spot urine samples for measurement of urinary iodine concentration (UIC). We will also measure height and weight in all children. We will collect a repeat, next-day spot urine sample in 1/3rd of children to adjust for intra-individual variation in spot UIC and calculate the distribution of population intake.

NCT ID: NCT04203342 Completed - Tinea Pedis Clinical Trials

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

Start date: December 11, 2019
Phase: Phase 3
Study type: Interventional

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.

NCT ID: NCT04015375 Completed - Acne Vulgaris Clinical Trials

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Start date: July 11, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.

NCT ID: NCT03824912 Completed - Tinea Pedis Clinical Trials

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

Start date: August 23, 2018
Phase: Phase 3
Study type: Interventional

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

NCT ID: NCT03650361 Completed - Acne Vulgaris Clinical Trials

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

Start date: September 17, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.

NCT ID: NCT03522441 Completed - Acne Vulgaris Clinical Trials

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

Start date: April 27, 2018
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.

NCT ID: NCT02865005 Completed - Acne Vulgaris Clinical Trials

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

Start date: February 2016
Phase: Phase 3
Study type: Interventional

Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.

NCT ID: NCT02651220 Completed - Acne Clinical Trials

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Start date: November 2015
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris

NCT ID: NCT02563054 Completed - Gastric Cancer Clinical Trials

A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Start date: April 2003
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer. The anticipated time on study treatment is at least 6 weeks and continued up to disease progression, and the target sample size is 300 individuals.

NCT ID: NCT02267746 Completed - Acne Vulgaris Clinical Trials

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabiorâ„¢ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.